SF3b inhibitors suppress proliferation of nonsmall cell lung cancer cells irrespective of EGFR mutation status
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard care for EGFR-mutant non-small cell lung cancer (NSCLC), but acquired